{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'R-ISS stage at original MM diagnosis study entry,', 'based on screening results (R-ISS Stage III versus', 'R-ISS Stage I or II) (Palumbo 2015). If data for', 'chromosomal abnormalities (CA) and serum lactate', 'dehydrogenase (LDH) required for R-ISS staging are', 'not available, patients will be assigned to the R-ISS', 'category corresponding to their ISS stage.', 'Related changes were made in Section 6.1.', 'Section 6.1: Overall Study Design', 'Added an exception to the requirement that patients will', 'To give patients in the Vd Arm who must', 'and Plan', 'either remain on study treatment until PD is confirmed by', 'terminate bortezomib prior to IRC-confirmed', 'Section 6.2: Crossover', 'the IRC or discontinue study treatment, complete the EoT', 'PD due to significant toxicities an opportunity', 'Visit, and be followed for survival. The exception only', 'to receive selinexor.', 'applies to patients in the Vd Arm who must terminate', 'bortezomib prior to IRCconfirmed PD due to significant', 'toxicities.', 'Section 6.2 Crossover', 'The following process will be used in order to prevent', 'premature crossover:', '1. Investigators will assess PD according to the', 'IMWG criteria including repeat testing if PD is', 'based on serum and/or urine M-protein,', 'quantitative immunoglobulins for IgA/IgD, or', 'serum free light chain (FLC). PD may also be', 'based on new or enlarging plasmacytoma(s) or', 'bone lesion(s) or on other symptoms and signs of', 'clinical progression that meet the IMWG criteria.', '2. All cases of PD must be confirmed by the IRC', 'prior to crossover.', 'Confidential', 'Page 123', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', '3. Crossover will not be permitted based purely on', 'Investigator-assessed progression that does not', 'meet any IMWG criteria for PD and cannot be', 'verified by IRC (eg, deteriorating performance', 'status).', '4. Crossover will not be permitted if dosing of', 'bortezomib is terminated before PD is confirmed', 'by the IRC, unless termination of bortezomib is', 'due to significant toxicities such as peripheral', 'neuropathy, and all treatment measures addressing', 'these toxicities are exhausted and documented', 'prior to bortezomib termination. Early termination', 'of bortezomib should be discussed and approved', 'by the Sponsor Medical Monitor in order to allow', 'crossover to SdX after progression is confirmed', 'by the IRC.', '5. Investigator-assessed presumptive PD events that', 'are not confirmed by the IRC will have their PFS', 'censored at the time of treatment discontinuation.', 'Related changes were made to the other sections noted.', 'Section 6.3: Data Safety', 'Added a more detailed description of the Data Safety', 'To align with the DSMB charter', 'Monitoring Board', 'Monitoring Board (DSMB).', 'Section 6.3 Data Safety Monitoring Board', 'An independent Data Safety Monitoring Board (DSMB)', 'will be set up for the study to review safety data for this', 'study. The DSMB will review safety data at intervals', 'outlined in the DSMB charter. The DSMB is made up of a', 'group of individuals with pertinent expertise that reviews,', 'on a predetermined schedule, safety data from this clinical', \"study. It is the DSMB's responsibility to weigh risks and\", \"benefits throughout the study's duration. The DSMB will\", 'provide oversight and safety monitoring of the study in', 'Confidential', 'Page 124', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'compliance with applicable regulations, legislation and', 'associated guidance materials for the nature of the study.', 'As appropriate, Tthe DSMB will provide', 'recommendations to the Sponsor regarding continuation,', 'modification, or discontinuation of the study based on the', 'safety results its assessment of the reviewed safety data.', 'This DSMB will be composed of 4 voting members (3', 'oncologists and an independent statistician) a Chairperson', 'and 3 voting members who will review safety data from', 'the study. The DSMB membership, functioning, and', 'procedures are described in the DSMB charter.', 'Section 3: Study Schematics and', 'Revised inclusion criterion #12, contraception', 'To align with the highly effective methods', 'Schedule of Assessments and', 'requirements, and guidance for pregnancy and', 'and pregnancy/breastfeeding guidance', 'Dosing for Study KCP-330-023', 'breastfeeding.', 'described in the new safety language template', '(Table 2: Schedule of', 'Section 7.2 Inclusion Criteria', 'provided by the Karyopharm', 'Assessments for Study KCP-330-', 'Pharmacovigilance Department', '023, footnote p)', 'Section 7.2: Inclusion Criteria', '12. Female patients of childbearing potential must agree to', 'use 2 methods of contraception (including 1 highly', 'Section 10.8.1: Contraception', 'effective and 1 effective method of contraception) and', 'Requirements', 'have a negative serum pregnancy test at Screening.', 'Section 12.3.1: Pregnancy and', 'Female patients of childbearing potential and fertile', 'Breastfeeding', 'Mmale patients who are sexually active with a female', 'of childbearing potential must use an highly effective', 'barrier methods of contraception if sexually active with', 'a female of childbearing potential. For both male and', 'female patients, effective methode of contraception', 'must be used throughout the study and for 3 months', 'following the last dose of study treatment. Highly', 'effective methods of contraception are listed in', 'Section 10.8.1.', 'Section 10.8.1 Contraception Requirements', 'Patients should not become pregnant or father a child', 'while on this study because the study treatments in this', 'Confidential', 'Page 125', 'Version 4.0']\n\n###\n\n", "completion": "END"}